GMP biologics market to reach $98.2 billion by 2033

The global good manufacturing practice (GMP) standards biologics market is growing rapidly, expected to be valued at around $52.7 billion in 2026 and projected to reach $98.2 billion by 2033, with a compound annual growth rate (CAGR) of 9.3% during the forecast period, according to Persistence Market Research

Growth is being driven by rising demand for monoclonal antibodies (MAbs), recombinant proteins, cell and gene therapies, and biosimilars, alongside increasing outsourcing of biologics manufacturing to contract development and manufacturing organizations (CDMOs). Continuous advances in single-use bioprocessing, automation, continuous manufacturing, and digital quality management systems are enabling manufacturers to improve production efficiency while maintaining strict compliance with US Food and Drug Administration (FDA), European Medicines Agency (EMA), and other global GMP standards.